Aspects of TNF inhibitor therapy in rheumatoid arthritis

Modern Rheumatology

Volumn 20, Issue 4, 2010, Pages 325-330

  Nam, Jackie ^a   Emery, Paul ^a  

^a CHAPEL ALLERTON HOSPITAL   (United Kingdom)

Author keywords

Certolizumab; Golimumab; Remission; Rheumatoid arthritis; TNF inhibitor

Indexed keywords

CERTOLIZUMAB PEGOL; GOLIMUMAB; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOSUPPRESSIVE AGENT; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

DRUG ANTAGONISM; HUMAN; IMMUNOLOGY; REMISSION; REVIEW; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; POLYETHYLENE GLYCOLS; REMISSION INDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78349284844     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/s10165-010-0277-7     Document Type: Review

References (23)

1. Feldmann M, Maim RN. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med. 2003; 9 (10): 1245 – 50.
2. Choo-Kang BS, Hutchison S, Nickdel MB, Bundick RV, Leish-man AJ, Brewer JM, et al. TNF-blocking therapies: an alternative mode of action? Trends Immunol. 2005; 26 (10): 518 – 22.
3. Raza K, Buckley CE, Salmon M, Buckley CD. Treating very early rheumatoid arthritis. Best Pract Res. 2006; 20 (5): 849 – 63.
4. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehen-sive review. Pharmacol Ther. 2008; 117 (2): 244 – 79.
5. Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Infiamm Bowel Dis. 2007; 13 (11): 1323 – 32.
6. Keystone E, Heijde D, Mason D Jr, Landewe R, Vollenhoven RV, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008; 58 (11): 3319 – 29.
7. Smolen J, Landewe RB, Mease P, Brzezicki J, Mason D, Luijtens K, et al. Efficacy and safety of certolizumab pegol plus metho-trexate in active rheumatoid arthritis: the RAPID 2 study A randomised controlled trial. Ann Rheum Dis. 2009; 68 (6): 797 – 804.
8. Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic ther-apy: the FAST4WARD study. Ann Rheum Dis. 2009; 68 (6): 805 – 11.
9. Emery P, Fleischmann RM, Moreland LM, Hsia EC, Strusberg I, Durez P et al. Golimumab (GLM), a new human anti-TNF-alpha monoclonal antibody, administered subcutaneously (SC) every 4 weeks in methotrexate-naive patients with active rheumatoid arhtirits (RA): a randomised, double-blind, placebo-controlled, GO-BEFORE study. Ann Rheum Dis. 2008;67[Suppl 21: 179.
10. Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, pla-cebo-controlled, dose-ranging study. Arthritis Rheum. 2008; 58 (4): 964 – 75.
11. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. Ann Rheum Dis. 2009; 68 (6): 789 – 96.
12. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breed-veld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis anti-tumor necrosis factor trial in rheumatoid arthritis with Concomitant Therapy Study Group (see comment). N Engl J Med. 2000; 343 (22): 1594 – 602.
13. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of eta-nercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.[see comment]. Lancet. 2004; 363 (9410): 675 – 81.
14. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006; 54 (1): 26 – 37.
15. Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J et al. Golimumab in patients with active rheu-matoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009; 374 (9685): 210 – 21.
16. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D et al. Comparison of methotrexate monotherapy with a combi-nation of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.[see comment]. Lancet. 2008; 372 (9636): 375 – 82.
17. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004; 50 (11): 3432 – 43.
18. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005; 52 (1): 27 – 35.
19. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, con-trolled trial.[see comment]. Arthritis Rheum. 2005; 52 (11): 3381 – 90.
20. Allaart CF, Breedveld FC, Dijkmans BA. Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt study. J Rheum. 2007; 80: 25 – 33.
21. van der Kooij SM, le Cessie S, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Zeben D, Kerstens PJ et al. Clinical and radiological efficacy of initial vs delayed treatment with inflix-imab plus methotrexate in patients with early rheumatoid arthri-tis. Ann Rheum Dis. 2009; 68 (7): 1153 – 8.
22. Tanaka Y, Takeuchi T, Miyasaka N, Koike T, Group RS. Dis-continuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: an interim report on RRR (remission induction by remicade in RA) study (EULAR abstract). Ann Rheum Dis. 2009;68[Suppl 31: 120.
23. Saleem B, Brown AK, Keen H, Nizam S, Freeston J, Karim Z et al. Disease remission state in patients treated with the combi-nation of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: a clinical and imaging comparative study. Arthritis Rheum. 2009; 60 (7): 1915 – 22.